SelectX Pharmaceuticals, Inc. is rapidly establishing itself as a leader in
the innovation and application of Genetic Chemistry for small molecule drug discovery. The Company focuses its
discovery and development efforts on antimicrobial and other therapeutics
that address unmet medical needs.
SelectX's most advanced program is a
preclinical aminoglycoside antibiotic that addresses the rapidly
growing gram negative hospital infection market. A second
program focuses on inflammation.
SelectX has developed two complementary technologies
– Directed Discovery™ and ComGene™
– to implement and exploit
the full potential of its Genetic Chemistry platform.
A second platform
– DART™ (Drug
and Antibiotic Resistance prediction Technology) –
permits the characterization of drug resistance prior to
its clinical emergence, allowing the development of the most durable
antibiotics.
Business Strategy
SelectX's business strategy is to rapidly develop a high potential
development pipeline through both proprietary and partnered programs
with leading pharmaceutical and biotechnology companies. The value of the Company's technologies resides, in part, in the capability of these technologies to significantly reduce both the time and cost of drug development; provide high-potential lead compounds and drug candidates; and are broadly applicable for the discovery of a wide range of therapeutics.